|
Title
Plasma cysteine and sulphate levels in patients with motor neurone,
Parkinson's and Alzheimer's disease.
Author
Heafield MT; Fearn S; Steventon GB; Waring RH; Williams AC; Sturman
SG
Source
Neurosci Lett, 1990 Mar, 110:1-2, 216-20
Abstract
Elevated plasma cysteine to sulphate ratios were found in patients
with Motor neurone disease (MND), Parkinson's disease (PD) and
Alzheimer's disease (AD). Cysteine and sulphate were measured
by colourimetric methods. Following recent discovery of a defect
in sulphoxidation and sulphation of xenobiotics in these diseases,
this finding confirms that endogenous sulphur metabolism is disturbed.The
mean cysteine:sulphate ratios (x 10(3] in fasting early morning
plasma were 506, 521 and 477 for MND, PD and AD whereas it was
96 for normal controls (P less than 0.001).This excess of cysteine
thiol groups may interfere with neural protein function. The
deficiency of sulphate ions may lead to reduced xenobiotic detoxification.
Title
Mechanisms involved in the regulation of key enzymes of cysteine
metabolism in rat liver in vivo.
Author
Bella DL; Hirschberger LL; Hosokawa Y; Stipanuk MH
Source
Am J Physiol, 1999 Feb, 276:2 Pt 1, E326-35
Abstract Little is known about mechanisms
of regulation of cysteine dioxygenase (CDO), gamma-glutamylcysteine
synthetase (GCS), and cysteine-sulfinate decarboxylase (CSDC)
in response to diet. Enzyme activity and Western and Northern
or dot blot analyses were conducted on liver samples from rats
fed a basal low protein diet or diets with graded levels of protein
or methionine for 2 wk. Higher levels of CDO activity and CDO
protein but not of CDO mRNA were observed in liver of rats fed
methionine or protein-supplemented diets, indicating that CDO
activity is regulated by changes in enzyme concentration.Lower
concentrations of the heavy or catalytic subunit of GCS (GCS-HS)
mRNA and protein, as well as a lower activity state of GCS-HS
in rats fed methionine- or protein-supplemented diets, indicated
that dietary regulation of GCS occurs by both pretranslational
and posttranslational mechanisms.Lower CSDC activity, CSDC protein
concentration, and CSDC mRNA concentration were found in rats
fed the highest level of protein, and regulation appeared to
involve changes in mRNA concentration. Regulation of key enzymes
of cysteine metabolism in response to diet determines the use
of cysteine for synthesis of its essential metabolites.
Title
High levels of dietary protein or methionine have different effects
on cysteine metabolism in rat hepatocytes.
Author
Bella DL; Stipanuk MH
Source
Adv Exp Med Biol, 1996, 403:, 73-84
Abstract
This study clearly indicates that relatively high levels of both
CDO and CSAD activity are needed for substantial taurine synthesis
and that protein and methionine supplementation, at equimolar
sulfur amino acid levels, are not equivalent in terms of their
effects on cysteine catabolic enzyme activities and cysteine
metabolism in hepatocytes. Evidence for a reciprocal regulation
of cysteine catabolism (or CDO activity) and GSH synthesis (or
gamma-glutamylcysteine synthetase activity) in rat liver was
also obtained. Although very high levels of protein and methionine
were fed in this study, previous studies with lower levels of
protein or methionine showed similar changes in cysteine metabolism.
Several questions regarding regulation of cysteine metabolism
remain unanswered. Beyond sulfur amino acid availability, animals
fed high protein diets appear to have other signals for regulation
of CDO and CSAD activities. These signals may be related to the
different hormonal and metabolic state of these animals. Furthermore,
little is known about the molecular mechanisms involved in the
observed changes in CDO and CSAD activities. The association
between CDO activity and CDO protein has not been evaluated.
Jerkins and Steele, using immunochemical detection and quantification
of CSAD protein in rat liver, showed that changes in CSAD protein
concentration were correlated to changes in CSAD activity. The
exact mechanisms or direct effectors which bring about changes
in CDO and CSAD activities have yet to be determined. Further
exploration of these potential regulatory mechanisms needs to
be conducted to better understand the response of cysteine sulfinate-dependent
cysteine catabolism to high levels of dietary protein or sulfur
amino acids.
Title
Sulphoxidation and sulphation capacity in patients with primary
biliary cirrhosis
Author
Davies MH; Ngong JM; Pean A; Vickers CR; Waring RH; Elias E
Source
J Hepatol, 1995 May, 22:5, 551-60
Abstract
We have previously reported an association of impaired S-oxidation
with primary biliary cirrhosis. In order to confirm and further
define this relationship, we retested S-oxidation capacity via
three metabolic pathways and sulphation capacity via a fourth
pathway. Metabolism of S-carboxymethyl-L-cysteine is polymorphic
-20% of healthy individuals being poor S-oxidisers. We found
26% with primary biliary cirrhosis were poor S-oxidisers, compared
with 36% with other liver disease and 25% of healthy controls.
Differences were not statistically significant. S-oxidation of
ranitidine is dependent upon flavin mono-oxygenases. We showed
a non-significant trend toward less S-oxide in primary biliary
cirrhosis and other liver disease, compared with healthy controls,
with no significant difference between disease groups. Conversion
of cysteine to sulphate depends predominantly on cysteine dioxygenase.
Impaired activity may be reflected by decreased plasma sulphate
and elevated cysteine. We found that the plasma cysteine: sulphate
ratio was significantly elevated not only in primary biliary
cirrhosis (p < 0.0001), but also in other liver disease (p
< 0.0001), compared with healthy individuals. Sulphation capacity
was studied by analysing paracetamol metabolism. Paracetamol
sulphate and sulphate: glucuronide ratio were reduced in primary
biliary cirrhosis compared with normal individuals, (p < 0.05).A
trend towards less sulphate in primary biliary cirrhosis compared
other liver disease was not significant (p = 0.42). We conclude
that although sulphation and some sulphoxidation pathways are
impaired in primary biliary cirrhosis, we can currently find
no evidence to substantiate the hypothesis that primary biliary
cirrhosis is a disease specifically associated with poor S-oxidation,
as assessed via these metabolic pathways.
Title
Abnormal sulphur oxidation in systemic lupus erythematosus
Author
Gordon C; Bradley H; Waring RH; Emery P
Source
Lancet, 1992 Jan, 339:8784, 25-6
Abstract
S-carboxy-L-methylcysteine was used to assess the activity of
the S-oxidation pathway of sulphur metabolism in 35 patients
with systemic lupus erythematosus (SLE); 25 (71%) showed impaired
sulphoxidation and 21 (60%) produced virtually no sulphoxides,
compared with 17 (36%) and 2 (4%), respectively, of 47 healthy
controls. The substrate/product ratio of cysteine oxygenase (plasma
cysteine/sulphate) was significantly higher in SLE patients than
in controls (median [interquartile range] 362 [224-588] vs 65
[44-111]; p less than 0.00001). The alternative pathway of sulphur
metabolism, S-methylation, catalysed by thiolmethyltransferase,
was not impaired in the SLE patients. There is a biochemical
difference in sulphur metabolism between SLE and rheumatoid arthritis,
since both pathways are impaired in the latter disorder.
Title
Increased prevalence of poor sulphoxidation in patients with
rheumatoid arthritis: effect of changes in the acute phase response
and second line drug treatment.
Author
Emery P; Bradley H; Gough A; Arthur V; Jubb R; Waring R
Source
Ann Rheum Dis, 1992 Mar, 51:3, 318-20
Abstract
A minority of normal subjects have an impaired ability to oxidise
sulphur, which is associated with an increased risk of side effects
when they receive sulphur containing drugs. In 114 patients with
rheumatoid arthritis a greatly increased prevalence of poor sulphoxidation
was found in 82 (72%) patients compared with 70/200 (35%) healthy
controls, 45/121 (37%) controls matched for age, and 4/35 (11%)
of the normal aged general population. In a longitudinal study
of 37 patients there was no significant alteration in sulphoxidation
status after the introduction of a second line drug or with marked
changes in the acute phase response. It seems, therefore, that
the poor sulphoxidation status in patients with RA is not an
epiphenomenon and may be an important factor in determining the
clinical features of rheumatoid disease.
Title
Genetic factors influencing the outcome of early arthritis--the
role of sulphoxidation status
Author
Emery P; Bradley H; Arthur V; Tunn E; Waring R
Source
Br J Rheumatol, 1992 Jul, 31:7, 449-51
Abstract
A minority of individuals have an impaired ability to oxidize
sulphur. An increased prevalence of this poor S-oxidation capacity
has been observed in patients with established rheumatoid arthritis
(RA). The role of this enzyme system in the development of disease
was studied by testing the S-oxidation capacity of 54 patients
with recent onset symmetrical poly-arthritis, who were followed
up at 1 and 4 years. Those patients with persistent disease at
1 year had a prevalence of poor S-oxidation of 69%. At 4 years
74% of those with a diagnosis of RA were poor S-oxidizers compared
to 31% of those who were asymptomatic (P less than 0.01). A defective
ability to oxidize sulphur appears to predispose to persistent
clinical disease.
Title
Structural organization and tissue-specific expression of the
gene encoding rat cysteine dioxygenase.
Author Tsuboyama N; Hosokawa Y; Totani
M; Oka J; Matsumoto A; Koide T; Kodama H
Address Department of Chemistry, Kochi
Medical School, Japan.
Source
Gene, 1996 Nov, 181:1-2, 161-5
Abstract Cysteine dioxygenase (CDO)
is a key enzyme involved in the metabolism of L-cysteine. Genomic
clones containing the 5'-flanking sequence of the rat CDO gene
were isolated and characterized. The CDO gene spanned about 15
kb, and comprised 5 exons. All boundaries between the exons and
introns matched the GT/AG rule. The major transcription start
point (tsp) was A at 213 bp upstream from the ATG codon. The
5'-flanking region contained a TATA-box-like sequence and putative
cis-acting regulatory elements. The 3' end of CDO was polyadenylated
at several sites. Northern blots of RNA from rat tissues revealed
the highest CDO mRNA level in the liver. Significant levels were
observed in the kidney, lung and brain, implying tissue-specific
differences in CDO promoter function.
Title
Hallervorden-Spatz disease: cysteine accumulation and cysteine
dioxygenase deficiency in the globus pallidus.
Author Perry TL; Norman MG; Yong VW;
Whiting S; Crichton JU; Hansen S; Kish SJ
Source Ann Neurol, 1985 Oct, 18:4,
482-9
Abstract
We describe neurochemical abnormalities found in the brains of
2 patients with autopsy-confirmed Hallervorden-Spatz (HS) disease.
In 1 patient, contents of cystine and of glutathione-cysteine
mixed disulfide in the globus pallidus were markedly elevated
above values for appropriate control subjects. Activity of cysteine
dioxygenase, which converts cysteine to cysteine sulfinic acid,
was reduced in the globus pallidus, but normal in the frontal
cortex and putamen of both patients. gamma-Aminobutyric acid
content was markedly decreased in the globus pallidus and substantia
nigra of both patients. These results suggest that cysteine accumulates
locally in the globus pallidus in Hallervorden-Spatz disease
as a result of an enzymatic block in the metabolic pathway from
cysteine to taurine. Accumulated cysteine may chelate iron, accounting
for the local increase in iron content in Hallervorden-Spatz
disease. The combined excess of cysteine and ferrous iron may
generate free radicals that damage neuronal membranes to cause
the typical morphological changes observed in this disorder.
Title
Metabolism of L-cysteine in guinea pig liver.
Author
Hosaki Y; Nishina H; Ubuka T
Source
Acta Med Okayama, 1986 Feb, 40:1, 11-5
Abstract
The metabolism of L-cysteine in guinea pig liver was studied.
Guinea pig liver contained 0.45 +/- 0.05 (mean +/- SD) mumol
of cysteine, 0.180 +/- 0.080 mumol of 3-mercaptolactate-cysteine
disulfide [S-(2-hydroxy-2-carboxyethylthio)cysteine, HCETC],
and 8.082 +/- 0.516 mumol of reduced glutathione per g of fresh
tissue. The taurine content was 0.912 +/- 0.158 mumol per g of
fresh liver. Cysteine dioxygenase (EC 1.13.11.20) activity was
several-fold lower than cysteine aminotransferase (EC 2.6.1.3)
activity. Lactate dehydrogenase (EC 1.1.1.27) activity was about
10-fold higher than 3-mercaptopyruvate sulfurtransferase (EC
2.8.1.2) activity. These results indicate that the oxidative
metabolism of L-cysteine in the guinea pig liver is not as active
as in the rat liver and that L-cysteine, at least in part, is
metabolized via the transaminative pathway, in which 3-mercaptopyruvate
is partly reduced to 3-mercaptolactate and is utilized to form
HCETC.
Title
Metabolism of cysteine, cysteinesulfinate and cysteinesulfonate
in rats fed adequate and excess levels of sulfur-containing amino
acids.
Author Stipanuk MH; Rotter MA Address
Source J Nutr, 1984 Aug, 114:8, 1426-37
Abstract The oxidation of cysteine,
cysteinesulfinate and cysteinesulfonate labeled with 14C in the
1- and 3-positions was studied in rats that had been fed diets
with adequate or excess cysteine. Consumption of excess cysteine
for 5 or 10 days resulted in an increase in hepatic cysteine
dioxygenase activity and a decrease in hepatic cysteinesulfinate
decarboxylase activity but had no effect on the oxidation of
the C-1 or C-3 of cysteine, cysteinesulfinate or cysteinesulfonate.
When the labeled compounds were administered by intraperitoneal
injection, 41% of cysteine, 100% of cysteinesulfinate and 37%
of cysteinesulfonate were oxidized over an 8-hour period. The
percentage of the oxidized cysteine, cysteinesulfinate and cysteinesulfonate
that was converted to taurine was calculated to be 83, 70 and
100%, respectively. When these same compounds were administered
intragastrically, the relative flux to taurine was lower for
all compounds; 41% of the oxidized cysteine, none of the cysteinesulfinate
and 11% of the oxidized cysteinesulfonate appeared to be converted
to taurine. Metabolism of intragastrically administered cysteine
may be more indicative of what happens to dietary cysteine, whereas
metabolism of intraperitoneally administered cysteine and cysteinesulfinate
may be more indicative of liver metabolism and of the metabolism
of endogenous cysteine and cysteinesulfinate.
Title Pathways of cysteine metabolism
in MND/ALS.
Author Pean A; Steventon GB; Waring
RH; Foster H; Sturman S; Williams AC Address School of Biochemistry,
University of Birmingham, Edgbaston, UK.
Source J Neurol Sci, 1994 Jul, 124
Suppl:, 59-61
Abstract Analysis of plasma from MND/ALS
patients has shown no significant differences in metabolism of
cysteine derivatives, although a sub-set of the population has
raised glutamate values. Cysteine dioxygenase was found to have
reduced activity in vitro, consistent with previous findings
of a high plasma cysteine/sulphate ratio.
Title Expression and localization of
cysteine dioxygenase mRNA in the liver, lung, and kidney of the
rat.
Author Shimada M; Koide T; Kuroda E;
Tsuboyama N; Hosokawa Y; Watanabe M Address Department of Anatomy,
Osaka Medical College, Japan.
Source Amino Acids, 1998, 15:1-2, 143-50
Abstract The expressions of cysteine
dioxygenase (CDO) gene in the liver, lung, skeletal muscle, and
kidney were studied by in situ hybridization with a cDNA probe
from rat liver CDO under normal conditions. Significant expression
of the CDO gene was detected in the liver, lung, and kidney,
but not skeletal muscle. In the liver, the signal was confined
to the cytoplasm of the hepatocytes. Furthermore, the signal
was stronger in the periportal than that in the perivenous areas.
In the lung, an intensive signal was found in the bronchiolar
epithelium. As to the kidney, an intensive signal was observed
in the distal convoluted tubules, while no signal was found in
the proximal convultions. Title Liver enzyme abnormalities in
Parkinson's disease. Author Tanner CM Address Clinical Center
for Parkinson's Disease and Movement Disorders, San Jose, California.
Source Geriatrics, 1991 Aug, 46 Suppl 1:, 60-3 Abstract If toxicant
exposure contributes to the cause of Parkinson's disease, poor
function of detoxifying enzymes could increase vulnerability
for Parkinson's disease. Although no hepatic enzyme system has
been shown universally to be dysfunctional in Parkinson's disease
patients, several have been suggested to be dysfunctional in
subgroups, such as those with young age at disease onset. Specific
enzymes implicated include several P450 enzymes, most notably
P450 IID6, and cysteine dioxygenase. If hepatic enzyme abnormalities
contribute to the development of Parkinson's disease, molecular
genetic techniques may allow the development of screening tests
to identify at-risk subjects in order to intervene with protective
therapies.
Title Abnormal liver enzyme-mediated
metabolism in Parkinson's disease: a second look.
Author Tanner CM Address Clinical Center
for Parkinson's Disease and Movement Disorders, San Jose, CA
95128.
Source Neurology, 1991 May, 41:5 Suppl
2, 89-91; discussion 92
Abstract If toxicant exposure contributes
to the cause of Parkinson's disease, poor function of detoxifying
enzymes could increase vulnerability for Parkinson's disease.
Although no hepatic enzyme system has been shown universally
to be dysfunctional in Parkinson's disease patients, several
have been suggested to be dysfunctional in subgroups, such as
those with young age at disease onset. Specific enzymes implicated
include several P450 enzymes, most notably P450 IID6, and cysteine
dioxygenase. If hepatic enzyme abnormalities contribute to the
development of Parkinson's disease, molecular genetic techniques
may allow the development of screening tests to identify at-risk
subjects in order to intervene with protective therapies.
Title The genetic origin of responses
to drugs.
Author Waring RH; Emery P Address School
of Biochemistry, University of Birmingham, UK.
Source Br Med Bull, 1995 Apr, 51:2,
449-61
Abstract Individual variation in drug
metabolism has been extensively investigated. Population studies
have shown that there is a wide range in metabolising ability
for all detoxification pathways; the distributions may be unimodal
(Gaussian) or polymodal, with subsets of individuals who differ
from the majority. These may be poor metabolisers (PM) or extensive
metabolisers (EM). In many cases, these phenotypes can be linked
with the genotype. Frequently the PM phenotype is more susceptible
to drug toxicity, while the EM phenotype requires increased dosage
for therapeutic benefit. In some cases, phenotypes or genotypes
appear to have increased susceptibility to clinical disease.
These ideas are discussed for the cytochrome P-450 isozymes,
FMO system, cysteine dioxygenase-linked oxidations, glucuronidation,
sulphation, acetylation, glutathione conjugation and methylation
pathways.
Title Plasma cysteine, cystine, and
glutathione in cirrhosis.
Author Chawla RK; Lewis FW; Kutner
MH; Bate DM; Roy RG; Rudman D
Source Gastroenterology, 1984 Oct,
87:4, 770-6
Abstract
Plasma contains three forms of cyst(e)ine: cysteine, cystine,
and protein-bound cysteine. The former is a thiol and the latter
two are disulfides. The levels of all three types of cyst(e)ine,
as well as the cysteinyl tripeptide glutathione, were measured
in the plasma of 14 normal and 10 cirrhotic individuals. All
subjects ate mixed foods. Some cirrhotic patients were studied
during nasogastric hyperalimentation with Vivonex (Norwich Eaton
Pharmaceuticals, Norwich, N.Y.) as well as during total parenteral
nutrition with FreAmine III (American McGaw, Irvine, Calif.);
neither formula contains cyst(e)ine. Regardless of the nature
of the diet, cirrhotic patients had significantly subnormal values
for cysteine, glutathione, and albumin. In addition, the following
significant changes were found to be diet-dependent: (a) elevated
methionine during Vivonex, (b) subnormal taurine during mixed
foods and total parenteral nutrition, (c) depressed protein-bound
cysteine during total parenteral nutrition, (d) depressed cyst(e)ine
thiol/disulfide ratio during mixed foods, and (e) depressed total
thiol during Vivonex and total parenteral nutrition. The data
indicate multiple abnormalities in sulfur metabolism in cirrhosis.
Title Role of the liver in interorgan
homeostasis of glutathione and cyst(e)ine.
Author Ookhtens M; Kaplowitz N
Address Department of Medicine, School
of Medicine, University of Southern California, Los Angeles 90033,
USA.
Source Semin Liver Dis, 1998, 18:4,
313-29
Abstract The most widely recognized
function of reduced glutathione (GSH) is its defense against
toxic compounds, whether exogenous, such as electophilic xenobiotics,
or endogenous, such as reactive oxygen species, generated during
normal oxidative metabolism and/or stress. However another no
less significant role of GSH-namely its function as a reservoir
and vehicle for packaging and transport of cyst(e)ine-has been
receiving increasing attention. Because GSH is relatively more
auto-oxidation resistant and stable than cyst(e)ine (CYSH), it
serves as the preferred form for storage and transport of the
latter especially in the extracellular and relatively much less
reduced (than intracellular) milieu, where CYSH oxidizes to cystine
(CYSS) rapidly. Over the past two decades, significant work has
been going on to delineate the intra- and extrahepatic (interorgan)
turnover, transport, and disposal of GSH and define the quantitative
role of these processes in interorgan homeostasis of GSH, CYSH,
and CYSS. These studies have identified the liver as the central
organ of interorgan GSH homeostasis, with sinusoidal GSH efflux
as the major determinant of plasma GSH, CYSH, CYSS, and thiol-disulfide
status of plasma. This article focuses on the principal components
and determinants of interorgan homeostasis of GSH and its breakdown
products. It also presents the current state of knowledge under
both normal and diseased states.
Title Distribution of oxidized and
reduced forms of glutathione and cysteine in rat plasma.
Author Lash LH; Jones DP
Source Arch Biochem Biophys, 1985 Aug,
240:2, 583-92
Abstract The distribution of the glutathionyl
moiety between reduced and oxidized forms in rat plasma was markedly
different than that for the cysteinyl moiety. Most of the glutathionyl
moiety was present as mixed disulfides with cysteine and protein
whereas most of the cysteinyl moiety was present as cystine.
Seventy percent of total glutathione equivalents was bound to
proteins in disulfide linkage. The distribution of glutathione
equivalents in the acid-soluble fraction was 28.0% as glutathione,
9.5% as glutathione disulfide, and 62.6% as the mixed disulfide
with the cysteinyl moiety. In contrast, 23% of total cysteine
equivalents was protein-bound. The distribution of cysteine equivalents
in the acid-soluble fraction was 5.9% as cysteine, 83.1% as cystine,
and 10.8% as the mixed disulfide with the glutathionyl moiety.
A first-order decline in glutathione occurred upon in vitro incubation
of plasma and was due to increased formation of mixed disulfides
of glutathione with cysteine and protein. This indicates that
plasma thiols and disulfides are not at equilibrium, but are
in a steady-state maintained in part by transport of these compounds
between tissues during the inter-organ phase of their metabolism.
The large amounts of protein-bound glutathione and cysteine provide
substantial buffering which must be considered in analysis of
transient changes in glutathione and cysteine. In addition, this
buffering may protect against transient thiol-disulfide redox
changes which could affect the structure and activity of plasma
and plasma membrane proteins.
Title Oxygen activating nonheme iron
enzymes.
Author Lange SJ; Que L Jr
Address Department of Chemistry Center
for Metals in Biocatalysis, University of Minnesota, 207 Pleasant
Street SE, Minneapolis, MN 55455, USA.
Source Curr Opin Chem Biol, 1998 Apr,
2:2, 159-72
Abstract The past year has witnessed
significant advances in the study of oxygen-activating nonheme
iron enzymes. Thirteen crystal structures of substrate and substrate
analog complexes of protocatechuate 3, 4-dioxygenase have revealed
intimate details about changes at the enzyme active site during
catalysis. Crystallographic data have established a 2-His-1-carboxylate
facial triad as a structural motif common to a number of mononuclear
nonheme iron enzymes, including isopenicillin N synthase, tyrosine
hydroxylase and naphthalene dioxygenase. The first metrical data
has been obtained for the high valent intermediates Q and X of
methane monooxygenase and ribonucleotide reductase, respectively.
The number of enzymes thought to have nonheme diiron sites has
been expanded to include alkene monooxygenase from Xanthobacter
strain Py2 and the membrane bound alkane hydroxylase from Pseudomonas
oleovorans (AlkB). Finally, synthetic complexes have successfully
mimicked chemistry performed by both mono- and dinuclear nonheme
iron enzymes, such as the extradiol-cleaving catechol dioxygenases,
lipoxygenase, alkane and alkene monoxygenases and fatty acid
desaturases.
Title Evidence of histidine coordination
to the catalytic ferrous ion in the ring-cleaving 2,2',3-trihydroxybiphenyl
dioxygenase from the dibenzofuran-degrading bacterium Sphingomonas
sp. strain RW1.
Author Bertini I; Capozzi F; Dikiy
A; Happe B; Luchinat C; Timmis KN
Address Department of Chemistry, University
of Florence, Italy.
Source Biochem Biophys Res Commun,
1995 Oct, 215:3, 855-60
Abstract The 1H NMR spectra of an aromatic
ring-cleaving extradiol dioxygenase, 2,2',3-trihydroxybiphenyl
dioxygenase of the dibenzofuran-degrading bacterium Sphingomonas
sp. strain RW1, are reported. In the catalytically active reduced
form of the monomeric enzyme (MW = 32 kDa), three broad strongly
downfield shifted signals were observed, two of which disappeared
in D2O solution. Their shifts and linewidths are consistent with
ring NH and meta-like protons of coordinated histidines. These
signals show strong sensitivity to the presence of the substrate.
The oxidized form of the enzyme shows no hyperfine shifted signals.
It is suggested that the high spin Fe(II) ion present in the
active form of the enzyme is coordinated by at least two histidines.
This is the first report of hyperfine shifted NMR signals being
detected for an extradiol dioxygenase.
Title Purification and characterization
of a cysteine dioxygenase from the yeast phase of Histoplasma
capsulatum.
Author Kumar V; Maresca B; Sacco M;
Goewert R; Kobayashi GS; Medoff G
Source Biochemistry, 1983 Feb, 22:4,
762-8
Abstract A cysteine dioxygenase, cysteine
oxidase (EC 1.13.11.20), has been purified from the cytosolic
fraction of yeast phase cells of the dimorphic fungus Histoplasma
capsulatum. The cysteine oxidase is an iron-containing dioxygenase
with a molecular weight of 10500 (+/- 1500) and is present only
in the yeast phase of the fungus. The enzyme is highly specific
for L-cysteine, with a Km of 2 X 10(-5) M in vitro. The product
of cysteine oxidation is cysteinesulfinic acid, as analyzed by
thin-layer chromatography and mass spectroscopy. To our knowledge,
this is the first cysteine oxidase isolated from a fungus, and
it probably plays an important role in the mycelial to yeast
phase transition of H. capsulatum during which redox potential
and cysteine levels are crucial factors.
|